Acurx Pharmaceuticals (NASDAQ:ACXP) reported fourth-quarter and full-year 2025 results highlighting a stronger cash position and continued progress in the development of its lead antibiotic candidate, ibezapolstat, for the treatment of Clostridioides difficile infection (C. difficile).
The company said its cash balance more than doubled year over year, reaching $7.6 million as of December 31, 2025, compared with $3.7 million at the end of 2024. Management attributed the increase to capital raises and tighter cost controls implemented throughout the year.
Research and development spending declined significantly as part of those efforts. R&D expenses totaled $0.3 million in the fourth quarter of 2025, down from $0.8 million in the same period a year earlier, reflecting a strategic focus on prioritizing key clinical programs.
Acurx also reported a net loss of $1.6 million for the quarter, an improvement of roughly 43% compared with Q4 2024.
Clinical progress with ibezapolstat
The company continues to advance ibezapolstat, its oral antibiotic candidate targeting C. difficile infections. According to the company, the drug demonstrated a 96% clinical cure rate in Phase 2 trials, supporting its potential as a differentiated treatment in a market where recurrence remains a major challenge.
Acurx said it plans to launch a new clinical trial program focused on recurrent C. difficile infection (rCDI). The trial aims to evaluate whether ibezapolstat could support a shift toward single-agent therapy, reducing dependence on multi-drug regimens and potentially lowering recurrence rates.
Market reaction
Despite the operational progress, Acurx shares fell about 15% in premarket trading following the earnings release, dropping to $5.01 from the previous close of $6.03.
The decline followed an unusually volatile period for the stock. Over the prior week, shares had surged more than 270%, and the stock remains over 100% higher year-to-date.
Analysts note that the sharp pullback may reflect profit-taking after the recent rally or broader market uncertainty rather than concerns about the company’s clinical progress.
Outlook
Looking ahead, Acurx plans to focus on advancing ibezapolstat through its next phase of clinical development while maintaining disciplined cost management.
Analysts covering the company maintain a consensus “Strong Buy” rating, with price targets ranging widely from $4 to $31, reflecting both the potential upside from successful clinical development and the risks associated with early-stage biotechnology programs.
Executive commentary
“Our financial position has strengthened considerably, allowing us to focus on advancing our clinical programs. We are committed to addressing the urgent need for effective C. difficile treatments,” said David Luci, President and Chief Executive Officer of Acurx Pharmaceuticals.
Key risks
Acurx faces several challenges common to development-stage biotech companies, including the need for additional capital to support future clinical trials, competition from larger pharmaceutical firms, and potential regulatory hurdles in securing approval for ibezapolstat.
During the earnings call, analysts also questioned management about cash management and the expected timeline for upcoming trials. Company executives said they intend to maintain financial flexibility while continuing to progress their research pipeline.